Objective: Histological grade is the most important factor for defining treatment strategies and predicting prognosis for salivary gland carcinoma (SGC). We examined factors affecting long-term recurrence and survival among intermediate-grade SGC (IGSGC) patients to define optimal treatment modalities and outcomes. Methods: We reviewed the clinical and pathological data on 108 IGSGC patients who underwent definitive surgery with or without postoperative radiotherapy. We compared treatment outcomes by treatment strategies such as surgical extent for the primary tumor, neck dissection, or postoperative radiotherapy. Results: During a 103-month median follow-up, local, regional, and distant recurrences were detected in 14 (13.0%), 3 (2.8%), and 21 (19.4%) patients, respectively. The 10-year locoregional control (LRC), distant metastasis-free survival (DMFS), and overall survival (OS) rates were 83.1, 76.0, and 80.1%, respectively. Multivariate analyses identified a nonparotid primary site as an independent prognostic factor for LRC (p = 0.018). Adenoid cystic carcinoma and a positive pN classification were significantly unfavorable prognostic factors for DMFS (p = 0.025 and p = 0.030, respectively); overall advanced stage was an independent prognostic factor for OS (p = 0.020). Surgical extent, elective neck dissection, and postoperative adjuvant radiotherapy did not significantly affect treatment outcomes. Conclusion: Patients with early-stage IGSGC of parotid origin can achieve favorable treatment outcomes with conservative surgery alone.

Keywords:
Salivary gland cancer, Intermediate grade, Survival, Prognostic factor, Treatment strategy
1.
Pinkston JA, Cole P: Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg 1999;120:834-840.
2.
Yoo SH, Roh JL, Kim SO, Cho KJ, Choi SH, Nam SY, Kim SY: Patterns and treatment of neck metastases in patients with salivary gland cancers. J Surg Oncol 2015;111:1000-1006.
3.
Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-2678.
4.
Suh JD, Cho JH: Trends in head and neck cancer in South Korea between 1999 and 2012. Clin Exp Otorhinolaryngol 2016;9:263-269.
5.
Walvekar RR, Filho PAA, Seethala RR, Gooding WE, Heron DE, Johnson JT, Ferris RL: Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies. Head Neck 2011;33:225-231.
6.
Boukheris H, Curtis RE, Land CE, Dores GM: Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:2899-2906.
7.
Brandwein MS, Ferlito A, Bradley PJ, Hille JJ, Rinaldo A: Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 2002;122:758-764.
8.
Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC, Salviano S: Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005;133:702-708.
9.
Seethala RR, Stenman G: Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland. Head Neck Pathol 2017;11:55-67.
10.
Seethala RR: An update on grading of salivary gland carcinomas. Head Neck Pathol 2009;3:69-77.
11.
Szanto PA, Luna MA, Tortoledo ME, White RA: Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer 1984;54:1062-1069.
12.
Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R: Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. Hum Pathol 2010;41:927-934.
13.
Cheuk W, Chan JK: Advances in salivary gland pathology. Histopathology 2007;51:1-20.
14.
Cho JK, Lim BW, Kim EH, Ko YH, Oh D, Noh JM, Ahn YC, Baek KH, Jeong HS: Low-grade salivary gland cancers: treatment outcomes, extent of surgery and indications for postoperative adjuvant radiation therapy. Ann Surg Oncol 2016;23:4368-4375.
15.
Hong HR, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY: Prognostic value of lymph node density in high-grade salivary gland cancers. J Surg Oncol 2015;111:784-789.
16.
Nam SJ, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY: Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 2016;23:4376-4383.
17.
Denaro N, Merlano MC, Russi EG: Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience. Clin Exp Otorhinolaryngol 2016;9:287-297.
18.
Lim YC, Lee SY, Kim K, Lee JS, Koo BS, Shin HA, Choi EC: Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 2005;41:1021-1027.
19.
Haderlein M, Scherl C, Semrau S, Lettmaier S, Uter W, Neukam FW, Iro H, Agaimy A, Fietkau R: High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. Head Neck 2016;38(suppl 1):E2041-E2048.
20.
Brandwein MS, Ivanov K, Wallace DI, Lettmaier S, Uter W, Neukam FW, Iro H, Agaimy A, Fietkau R: Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 2001;25:835-845.
21.
Nance MA, Seethala RR, Wang Y, Chiosea SI, Myers EN, Johnson JT, Lai SY: Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 2008;113:2082-2089.
22.
Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
23.
Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van den Ende PL, Burlage F: The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61:103-111.
24.
Dunn LA, Ho AL, Laurie SA, Pfister DG: Unmet needs for patients with salivary gland cancer. Oral Oncol 2016;60:142-145.
25.
Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, Rohrmeier C, Zenk J, Iro H: Predictors of cervical lymph node metastasis in salivary gland cancer. Head Neck 2014;36:517-523.
26.
Renehan AG, Gleave EN, Slevin NJ, McGurk M: Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br J Cancer 1999;80:1296-1300.
27.
Witten J, Hybert F, Hansen HS: Treatment of malignant tumors in the parotid glands. Cancer 1990;65:2515-2520.
28.
Kelley DJ, Spiro RH: Management of the neck in parotid carcinoma. Am J Surg 1996;172:695-697.
29.
Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schröder U, Eckel HE, Klussmann JP: High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 2003;129:720-723.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.